Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

…, P Moss, R Malladi, CF Craddock - Blood, The Journal …, 2012 - ashpublications.org
Strategies that augment a GVL effect without increasing the risk of GVHD are required to
improve the outcome after allogeneic stem cell transplantation (SCT). Azacitidine (AZA) up-…

[HTML][HTML] Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial

C Craddock, N Jilani, S Siddique, C Yap, J Khan… - Biology of Blood and …, 2016 - Elsevier
Disease relapse is the major causes of treatment failure after allogeneic stem cell
transplantation (SCT) in patients with acute myeloid leukemia (AML). As well as demonstrating …

Molecular MRD status and outcome after transplantation in NPM1-mutated AML

…, A Khan, R Salim, C Craddock… - Blood, The Journal …, 2020 - ashpublications.org
Relapse remains the most common cause of treatment failure for patients with acute myeloid
leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a …

GWAS meta-analysis of suicide attempt: identification of 12 genome-wide significant loci and implication of genetic risks for specific health factors

…, B Chaumette, A Corvin, N Craddock… - American journal of …, 2023 - Am Psychiatric Assoc
Objective: Suicidal behavior is heritable and is a major cause of death worldwide. Two large-scale
genome-wide association studies (GWASs) recently discovered and cross-validated …

Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature

CF Craddock, AE Houlton, LS Quek, P Ferguson… - Clinical Cancer …, 2017 - AACR
Purpose: Azacitidine (AZA) is a novel therapeutic option in older patients with acute myeloid
leukemia (AML), but its rational utilization is compromised by the fact that neither the …

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and …

…, BE Shaw, JL Byrne, C Brookes, CF Craddock… - Bone marrow …, 2014 - nature.com
EBV-associated post-transplant lymphoproliferative disease (PTLD) following Alemtuzumab-based
allo-SCT is a relatively uncommon and challenging clinical problem but has not …

[HTML][HTML] An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell …

…, D Milligan, RE Clark, NH Russell, C Craddock - …, 2016 - ncbi.nlm.nih.gov
Up to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after
induction chemotherapy-termed primary refractory acute myeloid leukemia. There is no …

[HTML][HTML] Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid …

C Craddock, D Slade, C De Santo… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Salvage options for patients who relapse after allogeneic stem-cell transplantation
(allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS) remain limited, …

[HTML][HTML] FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

…, E Conneally, C Craddock, D Culligan, M Dennis… - Leukemia, 2023 - nature.com
Patients with FLT3-mutated AML have a high relapse rate and suboptimal outcomes. Many
have co-mutations suitable for measurable residual disease (MRD) monitoring by RT-qPCR …

[HTML][HTML] Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid …

…, I Thomas, L Kjeldsen, M Dennis, C Craddock… - …, 2022 - ncbi.nlm.nih.gov
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients
with acute myeloblastic leukemia. We have previously shown that a RIC allograft, …